SCHEMBL320811

SCHEMBL320811

COc1c(-c2ccccc2)c(C(=O)c2ccc3nc(-c4ccccc4)oc(=O)c3c2)n2ccccc12

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 11/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ ALDH1A1 P00352 6/20 0.41
▸ HPGD P15428 4/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ F2 P00734 1/20 0.41
▸ KDM4E B2RXH2 4/20 0.41
▸ NPC1 O15118 3/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ LMNA P02545 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ ELANE P08246 1/20 0.40
▸ TP53 P04637 2/20 0.39
▸ CD74 P04233 1/20 0.39
▸ MIF P14174 1/20 0.39
▸ C1R P00736 1/20 0.38
▸ MBNL1 Q9NR56 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ MAPK10 P53779 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL320604 0.80 ELANE (0.41) MAPTALDH1A1HPGDKMT2AKDM4E
SCHEMBL692456 0.76 ELANE (0.62) MAPTHSD17B10ALDH1A1HPGDKMT2A
SCHEMBL1573008 0.75 MAPT (0.41) MAPTHSD17B10ALDH1A1HPGDKMT2A
SCHEMBL3597910 0.75 MAPT (0.47) MAPTNPC1SMN1; SMN2TP53
SCHEMBL11186148 0.75 MAPT (0.41) MAPTALDH1A1HPGDKMT2AKDM4E
SCHEMBL14927291 0.73 ELANE (0.44) MAPTHSD17B10ALDH1A1HPGDKMT2A
SCHEMBL6218698 0.73 MAPT (0.43) MAPTALDH1A1KMT2AKDM4ENPC1
SCHEMBL321669 0.73 HDAC1 (0.40) MAPTALDH1A1HPGDKMT2AKDM4E
SCHEMBL322335 0.72 MAPT (0.45) MAPTHSD17B10ALDH1A1KMT2AKDM4E
SCHEMBL321784 0.72 ELANE (0.62) MAPTHSD17B10ALDH1A1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590975-B1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-08-19 — — EP disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 — — US disclosed
EP-2590975-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-15 — — EP disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 — — US disclosed
WO-2012004731-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, INMT, IDO1 MAPT 961/4885HSD17B10 4071/4885ALDH1A1 3536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback